The Dong-A PharmTech Company Limited has just released a statement noting that it has initiated the process in China to get full approval for the selling and marketing of its erectile dysfunction drug Zydena. The first step of the process is to get import verification and then it will have to follow up with getting the Zydena drug to go through the clinical testing requirements of the China drug licensing authority, the SFDA. If all goes according to plan The Dong-A PharmTech Company is hoping that Zydena will be allowed to be sold in China by 2008.

Dong-A PharmTech has been busy with a double blind and placebo controlled clinical study for Zydena in America that involves 340 people in fifteen different places. Ukmedix will be looking at the results of that study next month when the results are due. Dong-A PharmTech has been selling Zydena in Korea for almost a year and it is competing well against the industry giants Viagra, Cialis and Levitra and they hope that soon they will be selling in many different countries abroad.

The move into China could be very lucrative as the pharmaceutical market there has been growing very fast especially in the last ten years as China finds new wealth. It is estimated that the drug market in China is worth 25 billion dollars and the erectile dysfunction drug market from that could be as much as two billion dollars as reports show that about half of all Chinese males between the ages of 40 to 70 suffer from some degree of erectile dysfunction.

Zydena can claim about 20% of the local market in South Korea and this is in close competition with Viagra made by Pfizer, Cialis made by Lilly and Levitra made by Bayer. Ukmedix is not aware of any plans for the introduction of Zydena into the UK or into Europe.